Filing Flows › Anika Therapeutics (ANIK) › Q2 2026
Anika Therapeutics (ANIK) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 29, 2026
Anika Therapeutics (ANIK) reported revenue of $32.6M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +10% from the quarter before. Operating margin was 9.1%, net earnings $3.3M (10.1% of revenue).
Anika Therapeutics, Q2 2026: revenue $32.6M (+16% year over year), operating margin 9.1%, net earnings $3.3M, operating cash flow −$684K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.6M | +10% | +16% |
| Gross profit | $21.2M | +12% | +48% |
| Operating profit | $3.0M | — | — |
| Net earnings | $3.3M | — | — |
| Operating cash flow | −$684K | — | — |
What changed
Revenue was $32.6M in Q2 2026, up 16% year over year and up 10% from the previous quarter. OEM Channel was the largest line at 57% of revenue. OEM Channel added $2.4M year over year (up 14%), 54% of the total change.
Gross margin was 65.1%, up 14.2 points from Q2 2025. Operating profit was $3.0M, a 9.1% margin (up 23.9 points year over year). Operating expenses fell 1% while revenue rose 16%. The fastest-growing cost line was Research & development (+16%). Net earnings were $3.3M. The effective tax rate was 2.1%.
Operating cash flow was −$684K. Non-cash charges added back $1.5M of depreciation and amortization and $1.8M of share-based compensation. Working capital and other items used $7.3M. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$2.1M.
Questions
What was Anika Therapeutics' revenue in the second quarter 2026?
Anika Therapeutics (ANIK) reported revenue of $32.6M for the second quarter 2026 (Q2 2026), +16% from a year earlier and +10% from the quarter before.
Was Anika Therapeutics profitable in the second quarter 2026?
Operating profit was $3.0M (9.1% of revenue) and net earnings $3.3M.
Source: Anika Therapeutics 10-Q on SEC EDGAR.